NCT02284906View on ClinicalTrials.gov

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 12, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

May 8, 2018

Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
DRUG

Pioglitazone

Pioglitazone tablets

DRUG

Placebo

Pioglitazone placebo-matching tablets

Trial Locations (43)

2113

North Ryde

3081

Heidelberg West

4215

Southport

6009

Nedlands

10019

New York

27705

Durham

28025

Concord

29401

Charleston

30033

Decatur

30329

Atlanta

32127

Port Orange

32940

Melbourne

32952

Merritt Island

33331

Weston

33445

Delray Beach

33449

Lake Worth

33709

St. Petersburg

33912

Fort Myers

44320

Akron

52242

Iowa City

53562

Middleton

60007

Elk Grove

Elk Grove Village

60640

Chicago

63141

St Louis

77030

Houston

84107

Salt Lake City

85006

Phoenix

85351

Sun City

89106

Las Vegas

92103

San Diego

08053

Marlton

CH-4012

Basel

BS16 1LE

Bristol

EX2 5DW

Exeter

PL6 8DH

Plymouth

W6 8RF

Hammersmith

EC1M 6BQ

London

M13 9NQ

Manchester

FY2 0JH

Blackpool

TW7 6FY

Isleworth

G20 0XA

Glasgow

PH2 7BH

Perth

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY